SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-094359
Filing Date
2024-08-09
Accepted
2024-08-09 08:00:29
Documents
13
Period of Report
2024-08-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acst-20240809.htm   iXBRL 8-K 40443
2 EX-99.1 acst-ex99_1.htm EX-99.1 163954
3 GRAPHIC img13613954_0.jpg GRAPHIC 10860
  Complete submission text file 0000950170-24-094359.txt   345512

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT acst-20240809.xsd EX-101.SCH 24881
15 EXTRACTED XBRL INSTANCE DOCUMENT acst-20240809_htm.xml XML 4701
Mailing Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540
Business Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540 609-649-9272
Acasti Pharma Inc. (Filer) CIK: 0001444192 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A8 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-35776 | Film No.: 241190442
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)